Field use of vaccinia-rabies recombinant vaccine for the control of sylvatic rabies in Europe and North America

1996 ◽  
Vol 15 (3) ◽  
pp. 947-970 ◽  
Author(s):  
B. BROCHIER ◽  
M. AUBERT ◽  
P-P PASTORET ◽  
E. MASSON ◽  
J. SCHON ◽  
...  
Keyword(s):  
North America ◽  
Recombinant Vaccine

scholarly journals The Early Development of the Vaccinia–Rabies Recombinant Vaccine Raboral®

2021 ◽  
Author(s):  
Richard Lathe ◽  
Marie Paule Kieny
Keyword(s):  
North America ◽  
Genetic Engineering ◽  
Early Development ◽  
Recombinant Vaccine ◽  
Rabies Vaccine ◽  
Recombinant Vaccinia ◽  
Engineering Company

The recombinant vaccinia–rabies vaccine, now known as Raboral®, has been widely used in Europe and North America to control/eliminate rabies in the principal wildlife vectors, and thus prevent human transmission. The origins of this vaccine are sometimes forgotten, although the formulation has not changed substantially in almost four decades. This groundbreaking vaccine was assembled by a team at a very young (at that time) genetic engineering company, Transgène, in Strasbourg, France. The joint leaders of the rabies vaccine team reflect, 36 years later, on the trials and tribulations that went hand in hand with the construction of the vaccine.

Sign in / Sign up

Export Citation Format

Share Document